Company Overview

For personal use only Market Leaders Competitive MOAT Strategy First to combine cannabinoids with established medicines for enhanced research outcomes and receive approval to investigate psilocybin in combination with psychotherapy for Generalized Anxiety Disorder. Regulatory Exclusivity We are pursuing FDA registration and marketing approval for each product and therapy under development. Regulatory approvals for commercialization in other jurisdictions to be sought e.g. EU, Canada, Australia, Japan, etc. Incannex Patents IHL drug candidates are considered novel and inventive due to the synergy between cannabinoid and off-patent medicines. Acquisition of APIRX completed in June adds 19 granted patents and 23 pending. Economic Potential With 28 active development programs within 6 active economic initiatives, there is significant value creation for our shareholders in both the near and long term. Investor Presentation 12

View entire presentation